Benzoxazine series of histidine kinase inhibitors as potential antimicrobial agents with activity against enterococci

Chemotherapy

Volumn 55, Issue 6, 2009, Pages 414-417

  Mueller Premru, Manica ^a   Zidar, Nace ^b   Cvitković Špik, Vesna ^a   Krope, Adrijana ^a   Kikelj, Danijel ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Antibacterial activity; Benzoxazine histidine kinase inhibitors; Broth macrodilution method; Enterococci

Indexed keywords

ANTIINFECTIVE AGENT; BENZOXAZINE DERIVATIVE; PROTEIN HISTIDINE KINASE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; DRUG STRUCTURE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BENZOXAZINES; ENTEROCOCCUS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 70849107855     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000263228     Document Type: Article

References (21)

1. Barreteau H, Kovač A, Boniface A, Sova M, Gobec S, Blanot D: Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol Rev 2008; 32: 168-207.
2. Kotnik M, Anderluh Štefanič P, Preželj A: Development of novel inhibitors targeting intracellular steps of peptidoglycan biosynthesis. Curr Pharm Design 2007; 13: 2283-2309.
3. Hilliard JJ, Goldschmidt RM, Licata L, Baum EZ, Bush K: Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob Agents Chemother 1999; 43: 1693-1699.
4. Frechette R, Weidner-Wells M: PCT Patent Application WO 97/17333 (15.5.1997). Chem Abstr 1997; 127: 50652.
5. Rowland SL, King GF: Histidine kinases as antimicrobial targets: prospects and pitfalls. Mini-Rev Med Chem 2007; 7: 1144-1154.
6. Stephenson K, Hoch JA: Developing inhibitors to selectively target two-component and phosphorelay signal transduction systems of pathogenic microorganisms. Curr Med Chem 2004; 11: 765-773.
7. Frlan R, Kovač A, Blanot D, Gobec S, Pečar S, Obreza A: Design and synthesis of MurC and MurD as potential antibacterial agents. Molecules 2008; 13: 11-30.
8. Moellering RC: Enterococcus species, Streptococcus bovis , and Leuconostoc species; in Mandell GA, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases, ed 6. Philadelphia, Elsevier Churchill Livingstone, 2005, pp 2411-2421.
9. Murray BE: Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-721.
10. Willems RJL, Top J, van Santen M, Robinson DA, Coque TM, Baquero F, et al: Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11: 821-828.
11. Top J, Willems R, Blok H, De Regt M, Jalink K, Troelstra A, et al: Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium . CMI 2006; 13: 316-346.
12. Renzoni A, Huggler E, Kelley WL, Lew D, Vaudaux P: Increased uptake and improved intracellular survival of a teicoplanin-resistant mutant of methicillin-resistant Staphylococcus aureus in non-professional phagocytes. Chemotherapy 2009; 55: 183-188.
13. Jones RN, Fritsche TR, Sader HS, Ross JE: Zyvox annual appraisal of potency and spectrum program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 2007; 59: 199-209.
14. Kainer M, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, et al: Response to emerging infection leading to outbreak of linezolid- resistant enterococci. Emerg Infect Dis 2007; 13: 1024-1030.
15. Enoch DA, Bygott JM, Daly ML, Karas A: Daptomycin. J Infect 2007; 55: 205-213.
16. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ: Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 2007; 60: 7-19. (Pubitemid 47073272)
17. Lentino JR, Narita M, Yu VL: New antimicrobial agents as therapy for resistant Grampositive cocci. Eur J Clin Microbiol Infect Dis 2008; 27: 3-15.
18. Sparo MD, Jones DG, Sanchez Bruni SF: Assessment of the in vitro efficacy of the novel antimicrobial peptide CECT7121 against human Gram-positive bacteria from serious infections refractory to treatment. Chemotherapy 2009; 55: 270-277.
19. Amsterdam D: Susceptibility testing of antimicrobials in liquid media; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams & Wilkins, 1996, pp 92- 111.
20. Barry AL, Reller LB, Miller GH, Washington JA, Schoenknect FD, Peterson LR, et al: Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides. J Clin Microbiol 1992; 30: 585-589.
21. Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: 18th Informational Supplement. Wayne, Clinical Laboratory Standards Institute, 2008, pp 1-181.